642 related articles for article (PubMed ID: 27194729)
1. Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice.
Shono Y; Docampo MD; Peled JU; Perobelli SM; Velardi E; Tsai JJ; Slingerland AE; Smith OM; Young LF; Gupta J; Lieberman SR; Jay HV; Ahr KF; Porosnicu Rodriguez KA; Xu K; Calarfiore M; Poeck H; Caballero S; Devlin SM; Rapaport F; Dudakov JA; Hanash AM; Gyurkocza B; Murphy GF; Gomes C; Liu C; Moss EL; Falconer SB; Bhatt AS; Taur Y; Pamer EG; van den Brink MRM; Jenq RR
Sci Transl Med; 2016 May; 8(339):339ra71. PubMed ID: 27194729
[TBL] [Abstract][Full Text] [Related]
2. [Gut microbiota and graft-versus-host disease: broad-spectrum antibiotic use increases post-allogeneic hematopoietic stem cell transplant graft-versus-host disease-related mortality].
Shono Y
Rinsho Ketsueki; 2017; 58(7):835-842. PubMed ID: 28781282
[TBL] [Abstract][Full Text] [Related]
3. Piperacillin-tazobactam vs. imipenem-cilastatin as empirical therapy in hematopoietic stem cell transplantation recipients with febrile neutropenia.
Jing Y; Li J; Yuan L; Zhao X; Wang Q; Yu L; Zhou D; Huang W
Clin Transplant; 2016 Mar; 30(3):263-9. PubMed ID: 26701371
[TBL] [Abstract][Full Text] [Related]
4. Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study.
Sanz MA; Bermúdez A; Rovira M; Besalduch J; Pascual MJ; Nocea G; Sanz-Rodríguez C;
Curr Med Res Opin; 2005 May; 21(5):645-55. PubMed ID: 15969864
[TBL] [Abstract][Full Text] [Related]
5. Anaerobic Antibiotics and the Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.
Tanaka JS; Young RR; Heston SM; Jenkins K; Spees LP; Sung AD; Corbet K; Thompson JC; Bohannon L; Martin PL; Stokhuyzen A; Vinesett R; Ward DV; Bhattarai SK; Bucci V; Arshad M; Seed PC; Kelly MS
Biol Blood Marrow Transplant; 2020 Nov; 26(11):2053-2060. PubMed ID: 32682948
[TBL] [Abstract][Full Text] [Related]
6. A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group.
Eklund AE; Nord CE
J Antimicrob Chemother; 1993 Jan; 31 Suppl A():79-85. PubMed ID: 8383657
[TBL] [Abstract][Full Text] [Related]
7. Imipenem-cilastatin versus piperacillin-tazobactam as monotherapy in febrile neutropenia.
Vural S; Erdem E; Gulec SG; Yildirmak Y; Kebudi R
Pediatr Int; 2010 Apr; 52(2):262-7. PubMed ID: 19744230
[TBL] [Abstract][Full Text] [Related]
8. Randomized comparison of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of patients with intra-abdominal infection.
Erasmo AA; Crisostomo AC; Yan LN; Hong YS; Lee KU; Lo CM
Asian J Surg; 2004 Jul; 27(3):227-35. PubMed ID: 15564167
[TBL] [Abstract][Full Text] [Related]
9. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis.
Jaccard C; Troillet N; Harbarth S; Zanetti G; Aymon D; Schneider R; Chiolero R; Ricou B; Romand J; Huber O; Ambrosetti P; Praz G; Lew D; Bille J; Glauser MP; Cometta A
Antimicrob Agents Chemother; 1998 Nov; 42(11):2966-72. PubMed ID: 9797234
[TBL] [Abstract][Full Text] [Related]
10. [Comparative study of piperacillin/tazobactam versus imipenem/cilastatin in febrile neutropenia (1994-1996)].
Figuera A ; Rivero N; Pajuelo F; Font P; Leyra F; de La Cámara R; Arranz R; María Fernández Rañada J
Med Clin (Barc); 2001 May; 116(16):610-1. PubMed ID: 11412645
[TBL] [Abstract][Full Text] [Related]
11. Retrospective evaluation of piperacillin-tazobactam, imipenem-cilastatin and meropenem used on surgical floors at a tertiary care hospital in Saudi Arabia.
Youssif E; Aseeri M; Khoshhal S
J Infect Public Health; 2018; 11(4):486-490. PubMed ID: 29153444
[TBL] [Abstract][Full Text] [Related]
12. Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections.
Brismar B; Malmborg AS; Tunevall G; Wretlind B; Bergman L; Mentzing LO; Nyström PO; Kihlström E; Bäckstrand B; Skau T
Antimicrob Agents Chemother; 1992 Dec; 36(12):2766-73. PubMed ID: 1336347
[TBL] [Abstract][Full Text] [Related]
13. Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital.
Saltoglu N; Dalkiran A; Tetiker T; Bayram H; Tasova Y; Dalay C; Sert M
Clin Microbiol Infect; 2010 Aug; 16(8):1252-7. PubMed ID: 19832720
[TBL] [Abstract][Full Text] [Related]
14. Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections.
Naber KG; Savov O; Salmen HC
Int J Antimicrob Agents; 2002 Feb; 19(2):95-103. PubMed ID: 11850161
[TBL] [Abstract][Full Text] [Related]
15. Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections.
Niinikoski J; Havia T; Alhava E; Pääkkönen M; Miettinen P; Kivilaakso E; Haapiainen R; Matikainen M; Laitinen S
Surg Gynecol Obstet; 1993 Mar; 176(3):255-61. PubMed ID: 8382381
[TBL] [Abstract][Full Text] [Related]
16. Cost efficacy of tazobactam/piperacillin versus imipenem/cilastatin in the treatment of intra-abdominal infection.
Dietrich ES; Schubert B; Ebner W; Daschner F
Pharmacoeconomics; 2001 Jan; 19(1):79-94. PubMed ID: 11252548
[TBL] [Abstract][Full Text] [Related]
17. Pharmacoeconomics of piperacillin/tazobactam and imipenem/cilastatin in the treatment of patients with intra-abdominal infections.
Jhee SS; Gill MA; Yellin AE; Berne TV; Heseltine PN; Appleman MD
Clin Ther; 1995; 17(1):126-35. PubMed ID: 7758055
[TBL] [Abstract][Full Text] [Related]
18. Co-administration of vancomycin and piperacillin-tazobactam is associated with increased renal dysfunction in adult and pediatric burn patients.
Hundeshagen G; Herndon DN; Capek KD; Branski LK; Voigt CD; Killion EA; Cambiaso-Daniel J; Sljivich M; De Crescenzo A; Mlcak RP; Kinsky MP; Finnerty CC; Norbury WB
Crit Care; 2017 Dec; 21(1):318. PubMed ID: 29262848
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of prophylactic treatment with intravenous piperacillin/tazobactam in patients undergoing hematopoietic stem cell transplantation.
Kroschinsky F; Wichmann G; Bornhauser M; Ordemann R; Schuler U; Ehninger G; Hanel M
Transpl Infect Dis; 2002 Sep; 4(3):132-6. PubMed ID: 12421457
[TBL] [Abstract][Full Text] [Related]
20. Impact of pre-transplant use of antibiotics on the graft-versus-host disease in adult patients with hematological malignancies.
Lee MW; Yeon SH; Heo BY; Kwon J; Ryu H; Lee HJ; Yun HJ; Jo DY; Song IC
Hematology; 2021 Dec; 26(1):96-102. PubMed ID: 33459581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
